<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03268642</url>
  </required_header>
  <id_info>
    <org_study_id>TJH-C20160202</org_study_id>
    <nct_id>NCT03268642</nct_id>
  </id_info>
  <brief_title>Clinical Assessment of New Treatment Regimen for Adult Fulminant Myocarditis</brief_title>
  <official_title>Assesment of Clinical Therapeutic Efficacy of &quot;Life-support Based Comprehensive Treatment Regimen&quot; for Adult Fulminant Myocarditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tongji Hospital</source>
  <brief_summary>
    <textblock>
      This is a retrospective cohort study to assess the clinical outcome of patients with&#xD;
      fulminant myocarditis using &quot;Life-support Based Comprehensive Treatment Regimen&quot; and&#xD;
      conventional therapy. In the present study, participants receive various treatment as part of&#xD;
      routine medical care without any assignment of specific interventions to them. The process of&#xD;
      treatment during hospitalization were recorded in medical chart and was reviewed by&#xD;
      independent research personnel.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 1, 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>death or cardiac transplantation</measure>
    <time_frame>through hospital discharge, an average of 10 days</time_frame>
    <description>The occurrence of death or cardiac transplantation was determined through direct contact with the patient or the family of the patient or review of the patient's medical record.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Fulminant Myocarditis</condition>
  <arm_group>
    <arm_group_label>Life-support Based Comprehensive Treatment Regimen group</arm_group_label>
    <description>meet all the following conditions:&#xD;
intravenous immune globulin;&#xD;
large dose of glucocorticoids;&#xD;
mechanical ventilation;&#xD;
hemodynamic support: intra-aortic balloon pump (IABP) or/and extracorporeal membrane oxygenation (ECMO);&#xD;
continuous renal replacement therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional therapy group</arm_group_label>
    <description>meet one of the following conditions:&#xD;
without/insufficient intravenous immune globulin;&#xD;
without/with various doses of glucocorticoid ;&#xD;
vasoactive drug;&#xD;
without/delayed mechanical ventilation;&#xD;
without/delayed hemodynamic support;&#xD;
without/delayed continuous renal replacement therapy.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        150 hospitalized patients with fulminant myocarditis will be enrolled in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  16 years of age or older;&#xD;
&#xD;
          -  Diagnosed as fulminant myocarditis:&#xD;
&#xD;
               -  Evidence of myocarditis on biopsy or increased biomarkers of myocardial injury&#xD;
                  (TNI and CK-MB and BNP or NT-pro-BNP);&#xD;
&#xD;
               -  Acute onset of symptoms of cardiac dysfunction: dyspnea, palpation, chest pain,&#xD;
                  and/or syncope;&#xD;
&#xD;
               -  Image for cardiac injury: marked diffused reduction in left ventricle wall&#xD;
                  movement, with dramatically decreased left ventricle ejection fraction (LVEF) &lt;&#xD;
                  45%;&#xD;
&#xD;
               -  Cardiogenic shock, e.g., systolic blood pressure â‰¤90 mmHg or mean arterial&#xD;
                  pressure &lt; 70mm Hg or a systolic blood pressure decrease &gt; 40 mm Hg, which is&#xD;
                  associated with the signs of hypofusion: cyanosis, cold extremities, oliguria,&#xD;
                  and/or changes in mental status.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Also considering acute coronary syndrome but unable to perform coronary angiography to&#xD;
             distinguish acute coronary syndrome from fulminant myocarditis;&#xD;
&#xD;
          -  Myocardial injury caused by sepsis, chemotherapeutical agents, or poisons;&#xD;
&#xD;
          -  Unstable hemodynamics or shock caused by hypovolemia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dao Wen Wang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yang Sun, MD candidate</last_name>
    <phone>86-27-83663280</phone>
    <email>d201578301@hust.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Sun, MD candidate</last_name>
      <phone>86-27-83663280</phone>
      <email>d201578301@hust.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 17, 2017</study_first_submitted>
  <study_first_submitted_qc>August 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2017</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Dao Wen Wang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Fulminant Myocarditis</keyword>
  <keyword>Retrospective cohort study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocarditis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

